Trial results

$RZLT — ersodetug

Rezolute, Inc. (RZLT) ersodetug: trial results in Tumor hyperinsulinism (tumor HI), 2026.

Research by Catalyst Intel · Published 2026-10-19 21:27 ET

The catalyst

"Enrollment is in progress and topline results are expected before the end of 2026."

— Rezolute, Inc., 8-K filed 2026-09-24 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id: RZLT-ERSODETUG-2026
Company: Rezolute, Inc.
Kind: Trial results
Indication: Tumor hyperinsulinism (tumor HI)
Window: 2026-12-01 – 2026-12-31
Status: bar_published

The bar

Published 2026-10-19 21:27 ET, before the event. The text below is the hashed text: paste it into the verify page and your browser will recompute the same digest.

At a glance

Pass if: A primary responder must meet the stated reduction-from-baseline threshold in IV GIR · At least the company-stated open-label responder count meets the primary GIR threshold

Great if (any one): At least the prior EAP percentage achieves complete discontinuation of IV dextrose/TPN; this is…

6 items we could not source — full detail below

EVENT RZLT-ERSODETUG-2026
SCORED SET evaluable
FLOOR floor_primary_gir_reduction_definition primary_gir_reduction_percent >= 50 | A primary responder must meet the stated reduction-from-baseline threshold in IV GIR.
BAR bar_primary_responder_count primary_gir_responder_count >= 9 | At least the company-stated open-label responder count meets the primary GIR threshold.
DIFF diff_complete_iv_dextrose_tpn_discontinuation complete_iv_dextrose_tpn_discontinuation_percent >= 75 | At least the prior EAP percentage achieves complete discontinuation of IV dextrose/TPN; this is supportive, not the registered primary endpoint.

SHA-256: 8f930339f9c4670b07ab0b4fa0ebeed8275a86d0a62266e84d3af6605f7096ab
Frozen: yes
Public post: https://x.com/i/web/status/2112354938688860637
OpenTimestamps: RZLT-ERSODETUG-2026.txt.ots, submitted 2026-10-21 03:45 ET. A proof that this hash existed by then, anchored in Bitcoin and checkable with the standard ots verify client beside the hashed text, without relying on us or on X.
Wayback Machine: snapshot of this page, 2026-10-19 21:27 ET

Criteria as committed

Floor — all must pass

Id	Field	Test	As written
`floor_primary_gir_reduction_definition`	`primary_gir_reduction_percent`	`>= 50`	A primary responder must meet the stated reduction-from-baseline threshold in IV GIR.

Bar — all must pass

Id	Field	Test	As written
`bar_primary_responder_count`	`primary_gir_responder_count`	`>= 9`	At least the company-stated open-label responder count meets the primary GIR threshold.

Differentiators — one upgrades IN_LINE to BEAT

Id	Field	Test	As written
`diff_complete_iv_dextrose_tpn_discontinuation`	`complete_iv_dextrose_tpn_discontinuation_percent`	`>= 75`	At least the prior EAP percentage achieves complete discontinuation of IV dextrose/TPN; this is supportive, not the registered primary endpoint.

What we could not source before the event

No document states the upLIFT primary-result analysis population; scored_set is null.
No separate formal alpha, confidence-interval, multiplicity, non-inferiority-margin, or power criterion was found.
No numerical upLIFT safety or tolerability veto threshold was found.
No manual comparator or options snapshot data were supplied.
No exact event date was found; company guidance is limited to the second half of 2026.
analysis population: evaluable — the registry lists a single-group study, which reports the patients it could assess; change it in the editor if the protocol says otherwise

Verdicts

No verdict has been published for this event yet.